SCHEMBL30860286

SCHEMBL30860286

Cc1cc(Nc2ncc(C(F)(F)F)c(Nc3cc4c(cc3N(C)S(C)(=O)=O)CCO4)n2)c(Cl)cc1N1CCC(N2CCN(C)CC2)CC1

nearest known ligand 0.48

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 10/20 0.48
▸ MET P08581 1/20 0.48
▸ ALK Q9UM73 6/20 0.44
▸ INSR P06213 5/20 0.44
▸ IGF1R P08069 3/20 0.44
▸ LRRK2 Q5S007 2/20 0.44
▸ PTK2 Q05397 2/20 0.43
▸ BRD4 O60885 1/20 0.39
▸ PLK1 P53350 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30860355 0.95 EGFR (0.49) EGFRMETALKINSRIGF1R
SCHEMBL26906717 0.92 EGFR (0.56) EGFRMETALKINSRIGF1R
SCHEMBL30860243 0.92 EGFR (0.51) EGFRMETALKINSRIGF1R
SCHEMBL26906997 0.91 EGFR (0.51) EGFRMETALKINSRIGF1R
SCHEMBL30860236 0.89 EGFR (0.55) EGFRMETALKINSRIGF1R
SCHEMBL26906511 0.87 EGFR (0.58) EGFRMETALKINSRIGF1R
SCHEMBL26906601 0.86 EGFR (0.62) EGFRMETALKINSRIGF1R
SCHEMBL30860392 0.86 EGFR (0.47) EGFRMETALKINSRIGF1R
SCHEMBL30860383 0.85 EGFR (0.55) EGFRMETALKINSRIGF1R
SCHEMBL30860402 0.85 EGFR (0.51) EGFRMETALKINSRIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024072075-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME 주식회사 테라펙스 2024-04-04 — — WO claimed
WO-2024072075-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME 주식회사 테라펙스 2024-04-04 — — WO disclosed
Send feedback